- Home
- PVLA vs CLVT Comparison
PVLA vs CLVT Comparison
Compare PVLA & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PVLA | CLVT |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United Kingdom |
| Employees | 14 | 12000 |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PVLA | CLVT |
|---|---|---|
| Price | $129.95 | $2.47 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 7 |
| Target Price | ★ $171.87 | $3.22 |
| AVG Volume (30 Days) | 228.3K | ★ 5.2M |
| Earning Date | 05-14-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $102,383.52 | $2.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.20 | $1.66 |
| 52 Week High | $151.18 | $4.77 |
Technical Indicators
Market Signals| Indicator | PVLA | CLVT |
|---|---|---|
| Relative Strength Index (RSI) | 58.51 | 53.03 |
| Support Level | $108.99 | $2.35 |
| Resistance Level | $133.06 | $2.70 |
| Average True Range (ATR) | 9.01 | 0.16 |
| MACD | 0.64 | -0.01 |
| Stochastic Oscillator | 83.37 | 66.36 |
Price Performance
Historical ComparisonAbout PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.